The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy

Y. Tahara, Y. Oshima, T. Sakamoto, T. Ishibashi, H. Inomala, D. R. Hinton, S. J. Ryan

Research output: Contribution to journalArticle

Abstract

Purpose. Hypencin, which has already been used as an antidepressant in clinically, has been shown to have potential antiviral and antineoplastic effects. The present study evaluates the clinical potential of hypericin for the treatment of proliferative vitreoretinopathy (PVR). Methods. PVR was induced in pigmented rabbits by intravitreal injection of 50,000 rabbit conjunctival fibroblasts (RCF) after vitrectomy. Subsequently, the eyes received intravitreal injection of either a sham injection (group A, control) or a single hypericin dose of 1 M (group B), 10 fiM (group C) or 100 jiM (group D). The eyes were examined ophthalmoscopically on days 1, 3, 7, 14, and 28 after surgery to evaluate the development and progression of PVR. The eyes were also examined by light microscopy. For the toxicity study, electroretinograms (ERG) and light microscopic analysis were performed 28 days after a single intravitreal injection of 100 U.M and 10 M hypericin. Results. In control eyes, membranes were well established by 7 days and were associated with retinal detachment. A significant inhibition of PVR were seen in group C and D compared with control eyes (P < 0.05). Differences between group A and B were not significant (P > 0.05). The toxicity study demonstrated no significant toxicity to the eye after administration of hypericin. Conclusions. The results suggest that intravitreal injection of hypericin is effective in reducing the incidence of experimental PVR and may have a potential for the treatment of human PVR.

Original languageEnglish
Pages (from-to)S664
JournalInvestigative Ophthalmology and Visual Science
Volume38
Issue number4
Publication statusPublished - Dec 1 1997

Fingerprint

Proliferative Vitreoretinopathy
Intravitreal Injections
Therapeutics
Rabbits
Light
Vitrectomy
Retinal Detachment
Antineoplastic Agents
Antidepressive Agents
Antiviral Agents
hypericin
Microscopy
Fibroblasts
Control Groups
Injections
Membranes
Incidence

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Tahara, Y., Oshima, Y., Sakamoto, T., Ishibashi, T., Inomala, H., Hinton, D. R., & Ryan, S. J. (1997). The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science, 38(4), S664.

The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy. / Tahara, Y.; Oshima, Y.; Sakamoto, T.; Ishibashi, T.; Inomala, H.; Hinton, D. R.; Ryan, S. J.

In: Investigative Ophthalmology and Visual Science, Vol. 38, No. 4, 01.12.1997, p. S664.

Research output: Contribution to journalArticle

Tahara, Y, Oshima, Y, Sakamoto, T, Ishibashi, T, Inomala, H, Hinton, DR & Ryan, SJ 1997, 'The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy', Investigative Ophthalmology and Visual Science, vol. 38, no. 4, pp. S664.
Tahara, Y. ; Oshima, Y. ; Sakamoto, T. ; Ishibashi, T. ; Inomala, H. ; Hinton, D. R. ; Ryan, S. J. / The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy. In: Investigative Ophthalmology and Visual Science. 1997 ; Vol. 38, No. 4. pp. S664.
@article{9f0e311552964c88a3bded8651f28f2f,
title = "The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy",
abstract = "Purpose. Hypencin, which has already been used as an antidepressant in clinically, has been shown to have potential antiviral and antineoplastic effects. The present study evaluates the clinical potential of hypericin for the treatment of proliferative vitreoretinopathy (PVR). Methods. PVR was induced in pigmented rabbits by intravitreal injection of 50,000 rabbit conjunctival fibroblasts (RCF) after vitrectomy. Subsequently, the eyes received intravitreal injection of either a sham injection (group A, control) or a single hypericin dose of 1 M (group B), 10 fiM (group C) or 100 jiM (group D). The eyes were examined ophthalmoscopically on days 1, 3, 7, 14, and 28 after surgery to evaluate the development and progression of PVR. The eyes were also examined by light microscopy. For the toxicity study, electroretinograms (ERG) and light microscopic analysis were performed 28 days after a single intravitreal injection of 100 U.M and 10 M hypericin. Results. In control eyes, membranes were well established by 7 days and were associated with retinal detachment. A significant inhibition of PVR were seen in group C and D compared with control eyes (P < 0.05). Differences between group A and B were not significant (P > 0.05). The toxicity study demonstrated no significant toxicity to the eye after administration of hypericin. Conclusions. The results suggest that intravitreal injection of hypericin is effective in reducing the incidence of experimental PVR and may have a potential for the treatment of human PVR.",
author = "Y. Tahara and Y. Oshima and T. Sakamoto and T. Ishibashi and H. Inomala and Hinton, {D. R.} and Ryan, {S. J.}",
year = "1997",
month = "12",
day = "1",
language = "English",
volume = "38",
pages = "S664",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "4",

}

TY - JOUR

T1 - The potential of hypericin in the treatment of experimental proliferative vitreoretinopathy

AU - Tahara, Y.

AU - Oshima, Y.

AU - Sakamoto, T.

AU - Ishibashi, T.

AU - Inomala, H.

AU - Hinton, D. R.

AU - Ryan, S. J.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Purpose. Hypencin, which has already been used as an antidepressant in clinically, has been shown to have potential antiviral and antineoplastic effects. The present study evaluates the clinical potential of hypericin for the treatment of proliferative vitreoretinopathy (PVR). Methods. PVR was induced in pigmented rabbits by intravitreal injection of 50,000 rabbit conjunctival fibroblasts (RCF) after vitrectomy. Subsequently, the eyes received intravitreal injection of either a sham injection (group A, control) or a single hypericin dose of 1 M (group B), 10 fiM (group C) or 100 jiM (group D). The eyes were examined ophthalmoscopically on days 1, 3, 7, 14, and 28 after surgery to evaluate the development and progression of PVR. The eyes were also examined by light microscopy. For the toxicity study, electroretinograms (ERG) and light microscopic analysis were performed 28 days after a single intravitreal injection of 100 U.M and 10 M hypericin. Results. In control eyes, membranes were well established by 7 days and were associated with retinal detachment. A significant inhibition of PVR were seen in group C and D compared with control eyes (P < 0.05). Differences between group A and B were not significant (P > 0.05). The toxicity study demonstrated no significant toxicity to the eye after administration of hypericin. Conclusions. The results suggest that intravitreal injection of hypericin is effective in reducing the incidence of experimental PVR and may have a potential for the treatment of human PVR.

AB - Purpose. Hypencin, which has already been used as an antidepressant in clinically, has been shown to have potential antiviral and antineoplastic effects. The present study evaluates the clinical potential of hypericin for the treatment of proliferative vitreoretinopathy (PVR). Methods. PVR was induced in pigmented rabbits by intravitreal injection of 50,000 rabbit conjunctival fibroblasts (RCF) after vitrectomy. Subsequently, the eyes received intravitreal injection of either a sham injection (group A, control) or a single hypericin dose of 1 M (group B), 10 fiM (group C) or 100 jiM (group D). The eyes were examined ophthalmoscopically on days 1, 3, 7, 14, and 28 after surgery to evaluate the development and progression of PVR. The eyes were also examined by light microscopy. For the toxicity study, electroretinograms (ERG) and light microscopic analysis were performed 28 days after a single intravitreal injection of 100 U.M and 10 M hypericin. Results. In control eyes, membranes were well established by 7 days and were associated with retinal detachment. A significant inhibition of PVR were seen in group C and D compared with control eyes (P < 0.05). Differences between group A and B were not significant (P > 0.05). The toxicity study demonstrated no significant toxicity to the eye after administration of hypericin. Conclusions. The results suggest that intravitreal injection of hypericin is effective in reducing the incidence of experimental PVR and may have a potential for the treatment of human PVR.

UR - http://www.scopus.com/inward/record.url?scp=33749195161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749195161&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749195161

VL - 38

SP - S664

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 4

ER -